Login to Your Account


Chromatin state plays role in T cells' will to fight

By Anette Breindl
Senior Science Editor

Friday, May 26, 2017

In the quest to understand what determines whether checkpoint blockade will work for a given patient, new research points to epigenetic factors. Tumor immunotherapy in the form of checkpoint blockade by PD-1 and CTLA-4 blockers has joined chemotherapy, radiation and targeted therapy as a pillar of cancer therapy.

To continue reading subscribe now to Science News

Learn More about Science News

Already a subscriber? Sign In or Buy now to activate your subscription